PROCESSING AND FABRICATION OF COMPOSITE SILK-BASED PLASTICS

SEQUENCE OF ACTIVATED PROTEIN C

NOVEL RECOMBINANT FACTOR C AND METHOD FOR PRODUCING THE SAME, AND METHOD FOR MEASURING ENDOTOXIN

NOVEL RECOMBINANT FACTOR C AND METHOD FOR PRODUCING THE SAME, AND METHOD FOR MEASURING ENDOTOXIN

NOVEL RECOMBINANT FACTOR C AND METHOD FOR PRODUCING THE SAME, AND METHOD FOR MEASURING ENDOTOXIN

CAMELID ANTIBODIES AGAINST ACTIVATED PROTEIN C AND USES THEREOF

METHODS OF MEDICAL TREATMENT WITH SUR1-TRPM4 CHANNEL INHIBITORS

METHODS FOR THE MEASUREMENT OF PROTEIN C AND ACTIVATED PROTEIN C

Recombinant Factor C and method for producing the same, and method for measuring endotoxin

MIRAC PROTEINS

TUNEABLE DELIVERY OF NANOPARTICLE BOUND ACTIVE PLASMIN FOR THE TREATMENT OF THROMBOSIS

NOVEL RECOMBINANT FACTOR C AND METHOD FOR PRODUCING THE SAME, AND METHOD FOR MEASURING ENDOTOXIN

METHODS OF MEDICAL TREATMENT WITH SUR1-TRPM4 CHANNEL INHIBITORS

IN VIVO POST-TRANSLATIONAL PROCESSING OF TARGET PROTEIN BY FURIN IN PLANTS: ENGINEERING, EXPRESSION AND PRODUCTION OF FUNCTIONAL ACTIVE HUMAN FURIN IN N. BENTHAMIANA PLANTS

Treatment of inflammatory skin disorders

Tuneable delivery of nanoparticle bound active plasmin for the treatment of thrombosis

Treatment of abnormal cutaneous scarring

Use of APC analogue for wound healing

Recombinant Factor C and method for producing the same, and method for measuring endotoxin

NOVEL RECOMBINANT FACTOR C AND METHOD FOR PRODUCING THE SAME, AND METHOD FOR MEASURING ENDOTOXIN

Extracellular histones as biomarkers for prognosis and molecular targets for therapy

Methods of medical treatment with SUR1-TRPM4 channel inhibitors

TREATMENT OF ABNORMAL CUTANEOUS SCARRING

Compositions and methods for treatment of ocular diseases

Recombinant factor C and method for producing the same, and method for measuring endotoxin

USE OF APC ANALOGUE FOR WOUND HEALING

Thrombin-thrombomodulin fusion proteins as protein C activators

EXTRACELLULAR HISTONES AS BIOMARKERS FOR PROGNOSIS AND MOLECULAR TARGETS FOR THERAPY

Mirac proteins

Tuneable delivery of nanoparticle bound active plasmin for the treatment of thrombosis

TREATMENT OF INFLAMMATORY SKIN DISORDERS

Markers for sepsis treatment

Mirac proteins

Treatment of abnormal cutaneous scarring

Use of APC analogue for wound healing

T cell balance gene expression, compositions of matters and methods of use thereof

METHODS FOR TREATING AND PREVENTING RADIATION INJURY USING ACTIVATED PROTEIN C POLYPEPTIDES

Extracellular histones as biomarkers for prognosis and molecular targets for therapy

Recombinant Factor C and method for producing the same, and method for measuring endotoxin

TREATMENT OF INFLAMMATORY SKIN DISORDERS

Modified SAK gene for the production of recombinant proteins

Modified factor VII or factor VIIa polypeptides

Mirac proteins

Mirac proteins

Extracellular histones as biomarkers for prognosis and molecular targets for therapy

Mirac proteins

Process for the purification of tissue plasminogen activator

Polynucleotides encoding therapeutic inhibitors of PAI-1

Protein fusion constructs possessing thrombolytic and anticoagulant properties

Modified SAK gene for the production of recombinant proteins

Protein C Zymogen and Methods of Use Thereof to Prevent Cancer Metastases

NON-NEUROTOXIC PLASMINOGEN ACTIVATING FACTORS FOR TREATING OF STROKE

Tissue plasminogen activator variant uses

Mirac proteins

CROSS-ß STRUCTURE COMPRISING AMYLOID-BINDING PROTEINS AND METHODS FOR DETECTION OF THE CROSS-ß STRUCTURE, FOR MODULATING CROSS-ß STRUCTURES FIBER FORMATION AND FOR MODULATING CROSS-ß STRUCTURE-MEDIATED TOXICITY

Mirac proteins

Cofilin knockdown host cells and uses thereof

PROTHROMBIC COMPLEX COMPOSITION

Modified vitamin K-dependent polypeptides

CHIMERIC TRUNCATED AND MUTANT VARIANT OF TISSUE PLASMINOGEN ACTIVATOR (T-PA) RESISTANT TO PLASMINOGEN ACTIVATOR INHIBITOR-1

Novel Glycosylated Polypeptides

Serine protease derivatives and uses in the prevention or the treatment of blood coagulation disorders

Preventing and treating sepsis

Polynucleotides encoding therapeutic inhibitors of PAI-1

Modified vitamin K-dependent polypeptides

PROTEIN C PATHWAY ASSOCIATED POLYMORPHISMS AS RESPONSE PREDICTORS TO ACTIVATED PROTEIN C OR PROTEIN C-LIKE COMPOUND ADMINISTRATION

Modified vitamin K-dependent polypeptides

tPA mutant in the treatment of acute brain injury and neurodegenerative disorders

TRANSGENIC PROTEINS FROM MULTI-GENE SYSTEMS, METHODS, COMPOSITIONS, USES AND THE LIKE RELATING THERETO

Mirac Proteins

METHODS AND COMPOSITIONS FOR ACTIVATED PROTEIN C WITH REDUCED ANTICOAGULANT PROPERTIES

Methods and Compositions for PDGF-C Activation and Inhibition

Inhibitors of PDE4 and Methods of Use

SERPINE1 POLYMORPHISMS ARE PREDICTIVE OF RESPONSE TO ACTIVATED PROTEIN C ADMINISTRATION AND RISK OF DEATH

ACTIVATED PROTEIN C VARIANTS WITH NORMAL CYTOPROTECTIVE ACTIVITY BUT REDUCED ANTICOAGULANT ACTIVITY

Chimeric plasminogen activators and their pharmaceutical use

Non-neurotoxic plasminogen activating factors for treating of stroke

Method for Production of a Bioengineered Form of Tissue Plasminogen Activator

Process for purifying recombinanat tissue plasminogen activator (TPA)

Extracellular histones as biomarkers for prognosis and molecular targets for therapy

Process for the Production of Recombinant Activated Human Protein C for the Treatment of Sepsis

Methods and compositions for PDGF-C activation and inhibition

Non-neurotoxic plasminogen activating factors for treating stroke

Cross-β structure comprising amyloid-binding proteins and methods for detection of the cross-β structure, for modulating cross-β structures fiber formation and modulating cross-β structure-mediated toxicity

Inhibitors of viral entry screening method

Modified enteropeptidase protein

MODIFIED VITAMIN K-DEPENDENT POLYPEPTIDES

Protein C variant

Methods for production of receptor and ligand isoforms

Carrier chimeric proteins, targeted carrier chimeric proteins and preparation thereof

Activated protein C variants with normal cytoprotective activity but reduced anticoagulant activity

Erythropoietin: remodeling and glycoconjugation of erythropoietin

Bifunctional variants of recombinant tissue-type plasminogen activator with platelet aggregation inhibitory activity

Cross-beta structures on microbial organisms

Remodeling and glycoconjugation of peptides

Modified vitamin K-dependent polypeptides

Diagnosis of blood clots using fibrin-binding proteins bound with contrast agents

Nitrosated and nitrosylated heme proteins

Protein C derivatives

Nitrosylation of protein SH groups and amino acid residues as a therapeutic modality

Non-neurotoxic plasminogen activating factors for treating of stroke

Bifunctional fusion protein with thrombolytic and anticoagulant activities and uses thereof

Methods and compositions for PDGF-C activation and inhibition

Cross-beta structure comprising amyloid-binding proteins and methods for detection of the cross-beta structure, for modulating cross-beta structures fibril formation and for modulating cross-beta structure-mediated toxicity

Cytoplasmic inhibition of gene expression

Thrombin-cleavable chimeric proteins

Methods for large scale production of recombinant DNA-derived tPA or K2S molecules

Production of recombinant polypeptides by bovine species and transgenic methods

Recombinant protein c variants

Method for producing a recombinant protein using pollen

Production of lysosomal enzymes in plants by transient expression

Pharmaceutical compositions of glycoconjugates

Protein C or activated protein C-like molecules

Protein C variants

Non-neurotoxic plasminogen activating factors for treating stroke

Activated protein C variants with normal cytoprotective activity but reduced anticoagulant activity